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Methadone is used worldwide for the treatment of heroin
addiction; however, fatal poisonings are increasingly reported. The
prevalence of CYP2B6 and µ-opioid receptor (OPRM1) gene
variations were examined between a postmortem population
where the deaths were associated with methadone and a live non-
drug-using control population using Taqman™ SNP Genotyping
assays. The CYP2B6*6 allele was higher in the postmortem
population, but the difference was not significant (P = 0.92). The
CYP2B6 T750C promoter variation was similar in frequency for
both populations. Linkage between T750C and CYP2B6*6 was
identified for both populations (P < 0.01). The prevalence of the
OPRM1 A118G variation was significantly higher in the control
population (P = 0.0046), which might indicate a protective
mechanism against opioid toxicity. Individual susceptibility to
methadone may be determined by screening for CYP2B6*6.
Introduction
The application of pharmacogenomics for the interpreta-
tion of drug toxicity and individual drug susceptibility is
steadily increasing and several studies indicate that the geno-
typing of single nucleotide polymorphisms (SNPs) may be a
useful forensic tool (1–3). Most functionally important SNPs
are located within genetic coding regions (exonic domains)
and are ideal candidates to examine interindividual drug re-
sponses (4). Gene variations in the Cytochrome P450 (CYP) en-
zymes can alter individual drug metabolizer status (3,5–7).
Similarly linkage between receptor variations and drug re-
sponse has been reported, with the µ opioid receptor gene
(OPRM1) recognized as a key variable in individual sensitivity
to opioids (8). A number of significant SNPs have also been
identified within critical non-coding regions (i.e., gene pro-
moter regions) (9).
Screening for SNPs involved in methadone action in vivo
could identify individuals susceptible to methadone toxicity in
addition to improving toxicological interpretation. CYP2B6 is
one of the cytochrome P450 enzymes responsible for
methadone metabolism. The T750C variant is located in the
proximal promoter region and has been linked with decreased
gene expression. The influence of T750C on methadone sus-
ceptibility is currently unknown. The CYP2B6*6/*6 genotype
results from the combination of the G516T and A785G SNPs
and has been associated with poor metabolism. CYP2B6*6/*6
is present at a frequency of about 6% in Caucasian populations
(7,10,11). In living subjects, the frequency of CYP2B6*1/*6
has previously been reported at 24–26% (12,13) with
CYP2B6*1/*4 at 26% (12). However, earlier work reported
higher frequencies in postmortem subjects whose deaths were
attributed to methadone at 40% and 37.5%, respectively (3).
This may be indicative of CYP2B6 involvement in methadone
toxicity. The work also documented a significant association be-
tween CYP2B6 variants and increased postmortem methadone
concentrations (3).
OPRM1 is of special interest as it is the preferential binding
target of methadone. The association between SNP frequencies
in the OPRM1 gene and drug response have been examined in
Hispanic (14), African-American (15), Caucasian (16), and
Japanese populations (17). The A118G SNP has been reported
at frequencies ranging between 2 and 48.5% across different
populations (14,15,18,19).
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Abstract
The purpose of this study was to explore the joint effects of
OPRM1 and CYP2B6 genes in predicting individual suscepti-
bility to methadone. Using SNP genotyping the prevalence of
the OPRM1 A118G variation, the CYP2B6 T750C promoter
variation and CYP2B6*4, *9, and *6 alleles were studied in 84
methadone associated fatalities comparing the gene frequen-
cies against a non-methadone-using control population.
Methods
Case subjects and controls
A population of 84 subjects whose deaths were associated
with methadone in the East of Scotland was selected. The con-
trol population consisted of 100 healthy non-methadone-using
volunteers from Bournemouth University. This study was ap-
proved by the Bournemouth University Ethics Committee.
DNA extraction and quantitation
Genomic DNA for the postmortem subjects was isolated
from leukocytes (sodium fluoride anticoagulated blood) using
the DNeasy Blood and Tissue Kit (Qiagen, Crawley, U.K.). For
the control group buccal cells were collected using the Epi-
centre Catch-All Swab and extracted in 150 µL of MasterAmp™
buccal extraction fluid (Epicentre Biotechnologies, Madison,
WI). All DNA samples were quantified using the Human Quan-
tifiler® Kit (Applied Biosystems, Warrington, U.K.) in accor-
dance with the manufacturer’s instructions.
Genotyping
The procedure for OPRM1 A118G, CYP2B6*4, *9, and *6
genotyping was described previously (3). For the CYP2B6 T750
promoter SNP samples were amplified by PCR to identify
homozygous wild type and heterozygous controls using primer
C2B6PrF (forward: 5' CAGGTTCAAGT-
GATTCTCTTG) and primer C2B6PrR (re-
verse: 5' CATGTTCAAAACTGAGAGGCT).
PCRs were performed with a reaction
volume of 50 μL, including 27.5 μL PCR
grade water, 10 μL of 5× GoTaq™ buffer,
3.0 mM MgCl2, 1 μL of 10 mM deoxynu-
cleoside triphosphates (dNTPs) (final con-
centration of 0.25 mM), 1 μL Forward and
Reverse primers, 10 ng/μL DNA, and 0.5
μL GoTaq DNA polymerase. PCR reactions
were performed with a Primus 96 ad-
vanced machine (Alpha Laboratories,
Eastleigh, U.K.). The cycling conditions
were as follows: initial denaturation at
95°C for 5 min; subsequent denaturation
at 95°C for 1 min; annealing at 65ºC for
30 s; primer extension at 72°C for 2 min,
repeated for 30 cycles, followed by final
extension at 72°C for 5 min. PCR prod-
ucts were visualized by electrophoresis
with a 2% Cyber Green-agarose gel on
blue light. Samples were purified using
the QIAquick PCR Purification Kit (Qiagen) in accordance
with the manufacturer’s instructions. DNA sequencing was
conducted by COGENICS (COGENICS, Essex, U.K.). Samples
were then genotyped for the T750C SNP using the validated
TaqMan® SNP Genotyping assay (Applied Biosystems, product
no. 4362691)
Statistical analysis
Data are presented as means ± SE of the mean. A Binary Lo-
gistic Regression model was used to examine the effects of
OPRM1 A118G, CYP2B6*4, *9, *6, age, sex, and race variables
between the control and postmortem population (95% confi-
dence intervals). T-Test and Fisher’s exact test were used to ex-
amine the difference between genotype frequencies for the
control and postmortem populations. Binary correlations were
used to examine the association between the CYP2B6 and
OPRM1 SNPs. A P value of ≤ 0.05 was considered to indicate
statistical significance. All analyses were performed with SPSS
Software (version 14.0).
Results
The 84 postmortem cases where methadone had been im-
plicated in the cause of death included 62 men and 22 women,
the majority of whom were Caucasian (98%). The mean age of
the case subjects was 33.2 ± 1.12 years (range 17–60). The
100 control subjects included 45 men and 55 women, the ma-
jority of whom were Caucasian (97%). The mean age of the
control subjects was 24 ± 0.72 years (range 18–55).
CYP2B6 G516T, A785G, and T750C frequency data
Of the 84 postmortem samples screened, 37 were genotyped
Figure 1. Heterozygous frequencies for OPRM1 A118G and CYP2B6 G516T, A785G, and T750C geno-
types.
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as heterozygous carriers of G516T (allele *9), a case percentage
of 44% and 2 were genotyped as homozygous carriers, a case
percentage of 2.4%. For the control group, 34% were geno-
typed as being heterozygous (a difference of 10%) and 3%
were homozygous for the G516T variant (Figures 1 and 2,
Table I). This difference was not statistically significant with a
P value of 0.92 (Fishers exact test). Heterozygous carriers of
A785G (allele * 4) for the postmortem group were identified in
40 cases (Table I), a frequency of 47.6% and 2.4% were
homozygous for the A785G variant, which is noticeably higher
than other reports from Caucasian populations (11–13,20).
For the control group, 38% of subjects were heterozygous for
A785G. The difference between the postmortem and control
frequencies was 9.6%, this result was not statistically signifi-
cant (P = 0.90). For the methadone-attributed deaths allele
*6 was identified in 39 subjects, an allelic frequency of 46.4 %,
which was higher than the control group where allele *6 was
identified in 36% of subjects (P = 0.92).
The T750C promoter region SNP has been linked with al-
terations in gene expression (10). In the postmortem popula-
tion 37 subjects were heterozygous for T750C, a case frequency
of 44%, a similar frequency to that identified in the control
population (49%). Sixteen postmortem
subjects were homozygous for the CC
genotype (19%) again a similar frequency
to the control population (17%) (Figure
2, Table I).
Linkage between the T750C, G516T,
and A785G gene variants was identified
in both populations (Table II). In the post-
mortem population the T750C, G516T,
and A785G variants were identified to-
gether in 17 cases (20%) and in the con-
trol population the SNPs were found in
17% of cases. Interestingly, wherever the
variant homozygote for T750C was iden-
tified, the G516T variant was not present.
For the postmortem population, the
variant T750C homozygote was found in
16 subjects (19%), and for the control
population, it was found in 17 subjects.
Only one of the nine postmortem sub-
jects also had the A785G variant, and for
the control group, only three subjects
also had the A785G variant.
OPRM1 A118G frequency data
In the postmortem group the A118G
SNP was found in 12 subjects a frequency
of 14.3% (Figure 1, Table I) which is a
similar result to previous studies (3,8,21).
No homozygote for the G allele was iden-
tified. In the control group 30 subjects
had the AG genotype and 2 subjects were
homozygous for the G allele. The differ-
ence in frequency between the groups
(15.7%) was statistically significant with a
P value of 0.0046.
No linkage was found between A118G
and T750C, G516T, and A785G in the con-
trol population. Interestingly, linkage was
identified between A118G and G516T and
A785G in the postmortem population
(Table II).
Age, sex, and race effects
Sex correlated with T750C in the post-
mortem population (–0.301 R2, P value =
0.005); however, the R2 value indicates
Figure 2. Homozygous variant frequencies for OPRM1 A118G and CYP2B6 G516T, A785G, and T750C
genotypes.
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Table I. CYP2B6 T750C SNP and CYP2B6*4, *9, and *6 Alleles and OPRM1
A118G SNP Frequencies for the Postmortem and Control Populations
Postmortem Population Control Population
Gene Variants (84 subjects) (100 subjects)
CYP2B6
T750C TT 31 (37%) 37 (37%)
(promoter region) TC 37 (44%) 44 (44%)
CC 16 (19%) 19 (19%)
A785G AA 42 (50%) 59 (59%)
(allele * 4) AG 40 (47.6%) 38 (38%)
GG 2 (2.4%) 3 (3%)
G516T GG 45 (53.6%) 63 (63%)
(allele * 9) GT 37 (44%) 34 (34%)
TT 2 (2.4%) 3 (3%)
Allele * 6 39 (46.4%) 36 (36%)
OPRM1
A118G AA 72 (85.7%) 68 (68%)
(exon 1) AG 12 (14.3%) 30 (30%)
GG 0 ( 2 (2%)
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only a modest correlation with the value < 0.5. This was not re-
peated in the control population (0.039 R2, P value = 0.699). No
SNP correlation with age was observed in the postmortem
population, but both G516T and A785G were associated with
age in the control population (0.256 R2, P value = 0.010; 0.293
R2, P value = 0.003, respectively), although the R2 values again
indicate a modest correlation of < 0.5. Age and sex were also
correlated with population (0.395 R2, P value = 0.001; –0.375
R2, P value = 0.001, respectively). Sex and age information for
both the postmortem and control populations are provided in
Table III.
Discussion
The importance of CYP2B6 and OPRM1 variations for indi-
vidual susceptibility to methadone was reported previously,
where subjects with the CYP2B6*4 (0.95 mg/L vs. 0.56 mg/L),
*9 (0.96 mg/L vs. 0.58 mg/L), and *6 (0.96 mg/L vs. 0.56 mg/L)
alleles were all associated with significantly higher postmortem
blood methadone concentrations compared with CYP2B6*1
(3). Therefore, the identification of methadone risk factors will
improve the toxicological interpretation of methadone-related
deaths at autopsy while assisting in the prevention of
methadone toxicity, particularly during the drug induction
phase.
The present study examined the prevalence of CYP2B6 and
OPRM1 SNPs in a postmortem population where the deaths
had been associated with methadone compared with a healthy
control population of non-methadone-using living subjects.
Earlier work noted higher incidences of the CYP2B6 G516T
Table II. Genotype Prevalence Between the Non-Drug-
Using Control Population and the Postmortem
Population whose Deaths Have Been Associated with
Methadone
Gene R2 P
Population Variants Value Value
Postmortem T750C & G516T –0.442* 0.001
T750C & A785G –0.389* 0.001
T750C & A118G –0.123 0.265
A118G & G516T 0.485* 0.001
A118G & A785G 0.495* 0.001
A785G & G516T 0.931* 0.001
Control T750C & G516T –0.365* 0.001
T750C & A785G –0.274* 0.006
T750C & A118G 0.072 0.479
A118G & G516T 0.058 0.572
A118G & A785G 0.072 0.479
A785G & G516T 0.903* 0.001
* Correlation is significant at the < 0.01 level (two-tailed).
Table III. CYP2B6 T750C, G516T, A785G and OPRM1 A118G Sex and Age Information for the Postmortem and Control
Populations
Postmortem Population Control Population
Male Male Female Female Male Male Female Female
Gene age mean age mean age mean age mean
Variants range age range age range age range age
CYP2B6
T750C
TT 18–51 (n = 17) 31 17–60 (n = 14) 35 19–47 (n = 18) 26 19–41 (n = 16) 25
TC 18–54 (n = 31)* 31 29–57 (n = 6)* 41 18–44 (n = 27) 26 19–55 (n = 22) 24
CC 21–56 (n = 14)* 33 30–34 (n = 2)* 32 18–34 (n = 10) 23 20–23 (n = 7) 21
A785G
AA 18–56 (n = 33) 34 17–57 (n = 9) 41 18–39 (n = 35) 24 18–36 (n = 24) 21
GA 20–54 (n = 28) 31 20–60 (n = 12) 30 20–44 (n = 19) 27 19–55 (n = 19) 26
GG 32 (n = 1) 32 37 (n = 1) 37 47 (n = 1) 47 22–24 (n = 2) 23
G516T
GG 18–56 (n = 36) 33 17–57 (n = 9) 45 18–43 (n = 38) 25 18–30 (n = 25) 21
GT 20–54 (n = 25) 30 20–60 (n = 12) 28 20–44 (n = 16) 27 19–55 (n = 18) 24
TT 32 (n = 1) 32 37 (n = 1) 37 47 (n = 1) 47 22–24 (n = 2) 23
OPRM1
A118G
AA 18–56 (n = 58) 32 17–60 (n = 14) 40 18–34 (n = 37) 24 19–55 (n = 31) 25
GA 20–54 (n = 4) 34 20–49 (n = 8) 31 20–47 (n = 16) 29 18–25 (n= 14) 20
GG (n = 0) 0 (n = 0) 0 21–25 (n = 2) 23 (n = 0) 0
* Indicates a sex correlation where P ≤ 0.5.
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and A785G variations in postmortem subjects (3) when com-
pared with previous studies sampling live subjects (11–13).
Similarly the results from this study report higher frequencies
of G516T and A785G in the postmortem population than the
control group (Figure 1, Table I). However, this difference was
not statistically significant (P = 0.92, P = 0.90, respectively) and
may be indicative of a trend that has been limited by sample
size. A larger number of postmortem subjects would elucidate
the association between G516T and A785G prevalence and
methadone susceptibility.
The T750C variant had a similar distribution across both
populations sampled suggesting that the presence of this
variant is not a suitable risk factor for methadone susceptibility
(Table I). However, when examining linkage between T750C
and G516T and T750C and A785G a significant association
was discovered (Table II). T750C has been reported to decrease
CYP2B6 expression (10). The work discussed previously re-
vealed the importance of the G516T and A785G variants for
methadone susceptibility with the CYP2B6*6 allele clearly cor-
relating with higher postmortem methadone concentrations
(3,7,11). It is therefore logical to postulate that, in a normal
population, subjects with this genotype will experience higher
methadone accumulation and are thus at greater risk of
methadone toxicity (3). To our knowledge, none of these sub-
jects were deliberate methadone overdose cases. Subjects with
all three CYP2B6 variants could therefore experience reduced
expression of an already poorly functioning gene. The resulting
effect on metabolism would likely involve methadone accu-
mulation and toxicity. The association of T750C, G516T, and
A785G was significant for both the postmortem population
and the control population suggesting the possibility of a hap-
lotype between these three CYP2B6 SNPs. Further investiga-
tion into the T750C SNP and gene expression is required to de-
termine the effects of both the 750 TC and 750 CC genotypes
for CYP2B6 expression. Furthermore, examination of T750C,
G516T, and A785G in a larger population is required to fully de-
termine whether this variation is linked with methadone sus-
ceptibility. The results from the current study revealed that
T750C presence is constant between the postmortem and con-
trol groups indicating that this variation is not a suitable risk
factor for methadone susceptibility.
Identification of genetic mutations that alter the functional
activity of OPRM1 may also explain interindividual responses
to methadone (22). A118G is located in the N-terminal region
of the receptor resulting in the loss of a putative N-glycosyla-
tion site which could result in alterations to OPRM1 expression
(23). The frequency of the A118G SNP was significantly higher
in the control group, with a 15.7% difference between popu-
lations for heterozygous subjects (P = 0.0046, Table I). Several
studies have reported that A118G may confer protection from
opioid toxicity (8,14,24). A118G has been associated with re-
ductions in cell surface receptors limiting the availability of
drug binding sites and as a result drug response (23). However,
it was previously reported that the A118G SNP may be associ-
ated with the lethal interaction between methadone and ben-
zodiazepines, although this may be a consequence of benzodi-
azepine induced µ-receptor up-regulation (3). A118G effects on
gene expression have been well documented (23,25). A study on
mRNA expression in postmortem brain tissue reported a 10-
fold reduction in protein levels for subjects with the G allele
(23). Furthermore, lower surface receptor expression and de-
creased forskolin-induced receptor activation has been identi-
fied in cell systems expressing the G allele (26). It seems log-
ical therefore that receptor function will be reduced in subjects
with the G allele. This may confer protection from opioid tox-
icity at therapeutic levels. However, these subjects will have a
reduced sensitivity of the µ-receptor, which could lead to
higher methadone concentrations in vivo before toxic effects
appear. As methadone has a long mean elimination half-life of
approximately 55 h (27), this could be especially pronounced in
drug abusing subjects, limiting any possible protective function
rendered by the G allele.
No linkage between the OPRM1 A118G genotype and
CYP2B6 T750C, G516T, and A785G genotypes was observed
for the control population in this study (Table II). However,
linkage was identified between A118G and G516T and A118G
and A785G in the postmortem population, this result is in
agreement with earlier results which documented a significant
association between A118G and G516T and A118G and A785G
in postmortem subjects (3). In this study G516T, A785G, and
A118G were found together in 8 of the postmortem cases
(9.5%) and 11% of the control population. An association be-
tween A118G, G516T, and A785G would have significant im-
pacts on methadone response. The CYP2B6*6 allele associ-
ates with increased susceptibility to methadone fatality and
A118G has been linked with increased heroin addiction (28).
Therefore, this combination of gene variants could lead to
subjects with increased tendency to drug addiction and a re-
duced ability to metabolize methadone (3).
The logistic regression model detected statistically signifi-
cant age and sex interactions; however, the R2 values indicate
that this association could be limited (Table II). Furthermore,
gender significantly correlated with CYP2B6 T750C in the
postmortem population (P < 0.01). As the frequency of this
SNP remained constant across both the postmortem and con-
trol populations, it is not known if this variation is suitable as
a risk factor for methadone susceptibility, and further investi-
gation is required. In the control population, CYP2B6 G516T
and A785G significantly correlated with age. However, as the
control group was made up of a student population, this may
have influenced this result.
Both age and sex influences on the opioid system have pre-
viously been described (29,30). Increased µ-opioid receptor
densities have previously been found to correlate with age,
with older subjects having significantly more receptors (29).
Gender influences could be linked with hormonal factors
which can influence drug absorption, disposition, metabolism,
and pharmacodynamics (31). This could contribute to differ-
ences in both drug action and response between males and fe-
males. It has been well documented that estrogen is involved
in the enhancement of psycho-stimulants in females (32–35).
Conversely, it has also been reported that estrogen may confer
protection against opioid toxicity as interindividual variation in
morphine potency is higher in males (30). A118G sex-specific
associations (36) have been reported previously, but the func-
tional significance of this is unclear (25).
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Alternatively, sex trends in drug abuse could be an influen-
tial factor in the significance reported in this study. It has
been well documented that drug abuse and mortalities from
drug overdose occur more frequently in males than females
(37,38), with reports of men being between two and three
times more likely to have a drug abuse/dependence disorder
(38). Furthermore, studies using animal models indicate that
sex differences in drug dependence may be a result of sexually
dimorphic development of the brain (33). Sociocultural and
economic parameters can also not be excluded, as years of ed-
ucation, employment status, medical health status, and inci-
dence of physical and sexual abuse are all underlying factors
contributing to the development of drug abuse and depen-
dence (31,39,40). The postmortem population examined in
this study only reported 22 females (26%), which could explain
the significance identified in this study for gender.
Conclusions
In summary, in this retrospective review of methadone-as-
sociated fatalities the CYP2B6*6 allele may be linked with in-
creased susceptibility to methadone particularly when in com-
bination with the CYP2B6 T750C promoter variation. It would
be interesting to conduct future studies that take into account
potential confounding factors such as the presence of all other
concomitant drugs, the mode of drug intake, postmortem in-
terval, prescription histories, medical histories, and case his-
tories to strengthen our findings.The association between the
prevalence of T750C, G516T, and A785G remained constant
across both the postmortem and control population. The role
of the OPRM1 A118G variation for methadone susceptibility re-
mains unclear. The higher prevalence of A118G in the control
population is in support of the theory that A118G is protective
against opioid toxicity (8,14,24). Although this protective func-
tion may work effectively with opioids such as morphine with
a relatively short elimination half-life (27), for methadone,
which has a significantly longer elimination half-life, this could
result in high concentrations accumulating in vivo, leading to
methadone toxicity and, in extreme cases, death. Furthermore,
no linkage was identified in this study between A118G and the
CYP2B6 G516T and A785G variations within the control pop-
ulation. It is suggested that a larger postmortem sample size is
required to effectively determine the role of A118G for
methadone response. Genotyping CYP2B6*6 homozygotes and
heterozygotes may therefore assist in reducing adverse reac-
tions to methadone during the drug induction phase while
serving as a useful tool for certifying methadone toxicity at au-
topsy.
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